Vera Therapeutics Stock (NASDAQ:VERA)
Previous Close
$41.41
52W Range
$14.20 - $51.61
50D Avg
$45.21
200D Avg
$40.74
Market Cap
$2.61B
Avg Vol (3M)
$749.67K
Beta
1.02
Div Yield
-
VERA Company Profile
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
VERA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| COGT | Cogent Biosciences, Inc. |
| TVTX | Travere Therapeutics, Inc. |
| TYRA | Tyra Biosciences, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| RLYB | Rallybio Corporation |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| ANAB | AnaptysBio, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| TARS | Tarsus Pharmaceuticals, Inc. |
| ETON | Eton Pharmaceuticals, Inc. |
| VTYX | Ventyx Biosciences, Inc. |
| ADAG | Adagene Inc. |
| RAPT | RAPT Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| ALDX | Aldeyra Therapeutics, Inc. |
| CYTK | Cytokinetics, Incorporated |
| CGEM | Cullinan Oncology, Inc. |
| CNTB | Connect Biopharma Holdings Limited |
| GLUE | Monte Rosa Therapeutics, Inc. |
| XLO | Xilio Therapeutics, Inc. |
| THRD | Third Harmonic Bio, Inc. |